Outcomes of Hospital-Acquired Bloodstream Infections in Critically Ill Adults

HA-BSIs are often caused by highly resistant pathogens and are associated with unfavorable prognoses.

Critically ill patients are at high risk for hospital-acquired bloodstream infections (HA-BSI), with consequences that include rising prevalence of resistant pathogens, delayed use of sufficient antimicrobial therapy, and mortality exceeding 30% (EUROBACT-1). EUROBACT-2 is a prospective international cohort study involving 2600 adult patients (64% male; median age, 64) with HA-BSI treated in 333 intensive care units (ICUs) between June 2019 and February 2021. Patients were admitted for non–COVID-associated respiratory failure (21%), sepsis or septic shock (20%), and COVID-19 (13%); 75% had at least one comorbid condition. HA-BSI sources included respiratory tract (27%), intravascular catheters (26%), primary BSI (16%), and the abdomen (15%)…

Reviewing Author

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Outcomes of Hospital-Acquired Bloodstream Infections in Critically Ill Adults

Topics

Reviewing Author